See the DrugPatentWatch profile for rinvoq
When does Rinvoq’s patent protection end?
Rinvoq (upadacitinib) patent and exclusivity timing depends on which specific patent (and which country) you mean. Patent term is usually limited by the earliest filing date plus the jurisdiction’s rules, but marketed-drug “end of protection” can also be extended by regulatory exclusivities, such as additional time for pediatric studies or other legally defined exclusivity periods.
DrugPatentWatch tracks patent families and estimated end dates for specific patents/exclusivities related to Rinvoq, which is often the most direct way to see the “until when” for protection in a given jurisdiction: https://www.drugpatentwatch.com/patent/rinvoq-rinvoq-upadacitinib
What “end” date should you look at: patents vs exclusivity vs generic entry?
People searching “how long until the patent ends” often mean one of these:
- Last patent expiration (an IP date, country-specific)
- Last regulatory exclusivity expiration (can block certain approvals even if patents lapse)
- Practical earliest generic/biosimilar market entry date (can depend on litigation outcomes, what’s actually expired, and approval pathways)
Because those dates can differ, you may see multiple end dates for the same product in patent tracking databases like DrugPatentWatch [1].
How to find the exact Rinvoq end date you need
To get the most accurate answer, you typically need:
- Country/region (e.g., US vs EU vs UK)
- Which form: the active ingredient upadacitinib (Rinvoq) is the key, but formulations/combination patents can vary
- Whether you want “last patent expires” or “regulatory exclusivity ends”
If you tell me the country (US, EU, UK, etc.), I can help interpret the relevant end dates shown by DrugPatentWatch for Rinvoq [1].
Sources
- DrugPatentWatch – Rinvoq (upadacitinib) patent information